XML 96 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other operating expenses
 12 Months Ended
Dec. 31, 2024
Analysis of income and expense [abstract]  
Other operating expenses Other operating expenses
Other operating expenses totaled €4,382 million in 2024, compared with €3,443 million in 2023 and €2,523 million in 2022.
Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of
Opella as a discontinued operation.
For 2024, this line item includes €3,955 million of expenses related to Regeneron (see Note C.1.), compared with €3,206 million for 2023
and €2,378 million for 2022 (as shown in the table below):
(€ million)
2024
2023
2022
Income & expense related to sharing of (profits)/losses under the Monoclonal
Antibody Alliance
(4,143)
(3,321)
(2,325)
Additional share of profit paid by Regeneron towards development costs(a)
833
668
434
Reimbursement to Regeneron of selling expenses incurred
(637)
(543)
(476)
Total - Monoclonal Antibody Alliance
(3,947)
(3,196)
(2,367)
Immuno-Oncology Alliance
—
—
16
Other (mainly Zaltrap and Libtayo)
158
217
1,120
Other operating income/(expenses), net related to Regeneron
(3,789)
(2,979)
(1,231)
of which amount presented in Other operating income (Note D.25.)
166
227
1,147
(a)As of December 31, 2024, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development
costs amounted to €1.6 billion, compared with €2.1 billion as of December 31, 2023 (see Note D.21.).
Charges to provisions for litigation and environmental risks are also recorded within this line item.